Page 18 - Biocon

Biocon diversifies business model, enters digital therapeutic segment

To launch Insulia for at-home management of diabetes in collaboration with Voluntis

Covid-19 treatment: A lowdown on possible cure and drugs being used

Business Standard takes a look at the common drugs that are being used in India for treating Covid-19 patients

Pharma industry steps up to cure black marketing of Covid-19 drugs

Some firms are now considering starting their own distribution centres in major cities

Plenty of catalysts for Biocon over the next few months, say analysts

Progress in biologics, projects in the pipeline driving prospects

Biocon eyes international markets to supply Itolizumab for Covid-19 therapy

Its partner Equillium is planning to carry out a clinical trial in the US, which could lead to huge spike in demand for the product

Biocon hits new high on DGCI nod to market Itolizumab for Covid treatment

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru

Biocon's drug Itolizumab gets regulator nod to treat Covid-19 patients

The drug which has got approval to treat moderate to severe Covid complications will be manufactured as an intravenous injection at Biocon's Bengaluru plant

Drug controller approves Biocon's psoriasis drug for emergency Covid-19 use

The firm presented the phase II clinical trial results to the drug regulator which were deliberated upon by the Subject Expert Committee of the DCGI's office

Pharma shares gain; Biocon, Granules hit record highs, Sun Pharma up 3%

At 10:27 am, Nifty Pharma index was up 1.5 per cent, as compared to 0.22 per cent decline in the benchmark Nifty50 index

Biocon to invest $200 million on capital expenditure in current fiscal

Biocon CEO and Managing Director Siddharth Mittal said the investment would be split across small molecules and biosimilar verticals

Biocon ties up with DKSH to distribute 7 products in Singapore, Thailand

Under the terms of the pact, DKSH will gain an exclusive license to register and commercialise the seven generic formulations from various therapeutic areas

Biocon gets a shot in the arm with FDA approval for insulin glargine

The drug will be major contributor in the firm's bid to reach $1 billion revenue target by FY22, says biologics CEO Hamacher

Biocon's Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

Shaw was picked from among 46 award winners from 41 countries and territories vying for the global title

Biocon MD Kiran Mazumdar-Shaw named EY World Entrepreneur Of The Year

The Biocon MD was picked from among 46 nominations from 41 countries

Biocon rallies 6%, hits record high on favourable ruling from US PTAB

Biocon's partner Mylan received a favourable ruling from U.S. Patent and Trademark Appeal Board (PTAB) on Sanofi's four device patents for Lantus SoloSTAR.

Biocon gets DCGI nod for CytoSorb device to treat Covid-19 patients

CytoSorb therapy reduces cytokine storm and the inflammatory response in Covid-19 patients through blood purification so that injury to organs may be mitigated or prevented

Logging in with facemasks: Offices look different as staff returns to work

Office life in these cities resumed on Monday, albeit cautiously and with full knowledge of the need to maintain social distancing.

Will invest Rs 2k cr in small molecules segment in 3-4 yrs: Biocon CEO & MD

In a Q&A, Biocon CEO and MD Siddharth Mittal explains why he believes his company is on track to achieve the $1 billion revenue target from the segment by 2022

MARKET WRAP: Indices end flat, Sensex slips 25 pts; financials, autos fall

All that happened in the markets today

Biocon shares slump over 4% as profit declines 42% in March quarter

The company's revenue, however, saw a muted growth of 6 per cent as compared to Q4 of FY19